Chesney Edward, McGuire Philip, Freeman Tom P, Strang John, Englund Amir
Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College London, De Crespigny Park, London SE5 8AF, UK.
Department of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK.
Ther Adv Psychopharmacol. 2020 Sep 9;10:2045125320954992. doi: 10.1177/2045125320954992. eCollection 2020.
Over the past 5 years, public interest in the potential health benefits of cannabidiol (CBD) has increased exponentially, and a wide range of over-the-counter (OTC) preparations of CBD are now available. A substantial proportion of the population appears to have used these products, yet the extent to which they are effective or safe is unclear. We reviewed the evidence for whether CBD has significant pharmacological and symptomatic effects at the doses typically found in OTC preparations. We found that most of the evidence for beneficial effects is derived from studies of pure, pharmaceutical grade CBD at relatively high doses. Relatively few studies have examined the effect of OTC CBD preparations, or of CBD at low doses. Thus, at present, there is little evidence that OTC CBD products have health benefits, and their safety has not been investigated. Controlled trials of OTC and low-dose CBD preparations are needed to resolve these issues.
在过去5年里,公众对大麻二酚(CBD)潜在健康益处的兴趣呈指数级增长,现在有各种各样的非处方(OTC)CBD制剂可供使用。相当一部分人似乎使用过这些产品,但它们的有效性或安全性尚不清楚。我们审查了关于CBD在非处方制剂中常见剂量下是否具有显著药理和症状作用的证据。我们发现,大多数关于有益效果的证据来自对相对高剂量的纯药用级CBD的研究。相对较少的研究考察了非处方CBD制剂或低剂量CBD的效果。因此,目前几乎没有证据表明非处方CBD产品具有健康益处,而且其安全性也尚未得到研究。需要对非处方和低剂量CBD制剂进行对照试验来解决这些问题。